PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence

Gastric adenocarcinoma is a leading cause of global cancer-related morbidity and mortality, and new therapeutic approaches are needed. Despite the improved outcomes with monoclonal antibodies targeting human epidermal growth factor receptor 2 and vascular endothelial growth factor receptor 2, durabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Phu N, Sarkissian, Sarmen, Chao, Joseph, Klempner, Samuel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533281/
https://www.ncbi.nlm.nih.gov/pubmed/28757801
http://dx.doi.org/10.2147/GICTT.S113525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533281/
https://www.ncbi.nlm.nih.gov/pubmed/28757801
http://dx.doi.org/10.2147/GICTT.S113525

Ejemplares similares